文献速递胃肠外科围术期管理与 ERAS

胃癌切除术后预防性腹腔引流与术后侵入性操作:ADIGE随机临床试验

Prophylactic Drain Placement and Postoperative Invasive Procedures After Gastrectomy: The Abdominal Drain After Gastrectomy (ADIGE) Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2025-01-01

ADIGE多中心随机非劣效试验纳入390例胃癌根治性胃切除术患者,比较预防性腹腔引流与不引流。

要点

  • 胃癌切除术后不放置预防性腹腔引流增加30天内再手术或经皮引流风险。
  • 引流组再手术率5.1%,不引流组12.4%,差异主要源于再手术。
  • 引流相关并发症仅4例,预防性引流总体安全。

核心结论

  • 胃癌切除术后避免预防性腹腔引流会增加术后侵入性操作(再手术或经皮穿刺引流)的风险,不支持常规省略引流。

研究设计与样本

  • 803例评估,404例随机(1:1引流组 vs 不引流组),390例纳入改良意向性分析(mITT)。
  • 纳入胃癌行根治性胃次全或全切除术患者,排除<18岁、严重合并症及研究范围外手术。

主要发现

  • 引流相关并发症发生4例。

关键数值与推荐

  • 主要终点为术后30天内再手术或经皮引流,非劣效界值:90%CI上限不超过3.56%。
  • 样本量计算:80%把握度,10%脱落率,需404例(每组202例)。
  • 随机分组至胃肠重建前,外科医生和患者均设盲。

临床怎么用

  • 胃癌切除术后应常规放置预防性腹腔引流,以降低再手术或经皮引流风险。

局限性

  • 引流相关并发症仅4例,但未详细说明类型。
  • 未来需识别高危群体以优化引流决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence suggests that prophylactic abdominal drainage after gastrectomy for cancer may reduce postoperative morbidity and hospital stay but this evidence comes from small studies with a high risk of bias. Further research is needed to determine whether drains safely meet their primary purpose of identifying and managing postoperative intraperitoneal collections without the need for reoperation or additional percutaneous drainage. OBJECTIVE: To determine whether avoiding routine abdominal drainage increased postoperative invasive procedures. DESIGN, SETTING, AND PARTICIPANTS: The Abdominal Drain in Gastrectomy (ADIGE) Trial was a multicenter prospective randomized noninferiority trial. Enrollment spanned from December 2019 to January 2023. Follow-up evaluations were completed at 30 and 90 days. Eleven centers within the Italian Research Group for Gastric Cancer, encompassing both academic medical centers and community hospitals, were included. Patients with gastric cancer undergoing subtotal or total gastrectomy with curative intent were eligible, excluding those younger than 18 years, with serious comorbidities, or undergoing procedure types outside the scope of the study. Of 803 patients assessed for eligibility, 404 were randomized and 390 were included in final analyses. INTERVENTIONS: Patients were randomized 1:1 into prophylactic drain or no drain arms. MAIN OUTCOMES AND MEASURES: The primary end point was a modified intention-to-treat (mITT) analysis measuring reoperation or percutaneous drainage within 30 postoperative days. The null hypothesis was rejected when the 90% CI upper limit of the proportion difference did not exceed 3.56%. The calculated sample size to achieve 80% power with a 10% dropout rate was 404 patients (202 in each group). Surgeons and patients were blinded until gastrointestinal reconstruction. RESULTS: Of the 404 patients randomized 226 (57.8%) were male; the median (IQR) age was 71 (62-78) years. Intraoperative identification of nonresectable disease occurred in 14 patients, leading to their exclusion from the study, leaving 390 patients. In the mITT analysis, 15 patients (7.7%) in the drain group needed reoperation or percutaneous drainage by postoperative day 30 vs 29 (15%) in the no drain group, favoring the drain group (difference, 7.2%; 90% CI, 2.1-12.4; P = .02). Of note, the difference in the primary composite end point was entirely due to a similar difference in reoperation (5.1% in the drain group vs 12.4% in the no drain group; P = .01). Drain-related complications occurred in 4 patients. CONCLUSIONS AND RELEVANCE: The findings of this study indicate that refraining from prophylactic drain use after gastrectomy heightened the risk of postoperative invasive procedures, discouraging its avoidance. Future studies identifying high-risk groups could optimize prophylactic drainage decisions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04227951.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Weindelmayer J, Mengardo V, Ascari F, et al. Prophylactic Drain Placement and Postoperative Invasive Procedures After Gastrectomy: The Abdominal Drain After Gastrectomy (ADIGE) Randomized Clinical Trial. JAMA Surg. 2025. PMID: 39602143. doi:10.1001/jamasurg.2024.5227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。